Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth

Ningning Liu; Xiaofen Li; Hongbiao Huang; Chong Zhao; Siyan Liao; Changshan Yang; Shouting Liu; Wenbin Song; Xiaoyu Lu; Xiaoying Lan; Xin Chen; Songgang Yi; Li Xu; Lili Jiang; Canguo Zhao; Xiaoxian Dong; Ping Zhou; Shujue Li; Shunqing Wang; Xianping Shi; Ping Q. Dou; Xuejun Wang; Jinbao Liu

doi:10.18632/oncotarget.2113

Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth

Ningning Liu, Xiaofen Li, Hongbiao Huang, Chong Zhao, Siyan Liao, Changshan Yang, Shouting Liu, Wenbin Song, Xiaoyu Lu, Xiaoying Lan, Xin Chen, Songgang Yi, Li Xu, Lili Jiang, Canguo Zhao, Xiaoxian Dong, Ping Zhou, Shujue Li, Shunqing Wang, Xianping ShiPing Q. Dou, Xuejun Wang, Jinbao Liu

Research output: Contribution to journal › Article › peer-review

101 Scopus citations

Abstract

Proteasomes are attractive emerging targets for anti-cancer therapies. Auranofin (Aur), a gold-containing compound clinically used to treat rheumatic arthritis, was recently approved by US Food and Drug Administration for Phase II clinical trial to treat cancer but its anti-cancer mechanism is poorly understood. Here we report that (i) Aur shows proteasome-inhibitory effect that is comparable to that of bortezomib/Velcade (Vel); (ii) different from bortezomib, Aur inhibits proteasome-associated deubiquitinases (DUBs) UCHL5 and USP14 rather than the 20S proteasome; (iii) inhibition of the proteasome-associated DUBs is required for Aur-induced cytotoxicity; and (iv) Aur selectively inhibits tumor growth in vivo and induces cytotoxicity in cancer cells from acute myeloid leukemia patients. This study provides important novel insight into understanding the proteasome-inhibiting property of metal-containing compounds. Although several DUB inhibitors were reported, this study uncovers the first drug already used in clinic that can inhibit proteasome-associated DUBs with promising anti-tumor effects.

Original language	English (US)
Pages (from-to)	5453-5471
Number of pages	19
Journal	Oncotarget
Volume	5
Issue number	14
DOIs	https://doi.org/10.18632/oncotarget.2113
State	Published - 2014
Externally published	Yes

Keywords

Auranofin
Cancer
Deubiquitinase
Proteasome

ASJC Scopus subject areas

Oncology

Access to Document

10.18632/oncotarget.2113

Fingerprint Dive into the research topics of 'Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth'. Together they form a unique fingerprint.

Cite this

Liu, N., Li, X., Huang, H., Zhao, C., Liao, S., Yang, C., Liu, S., Song, W., Lu, X., Lan, X., Chen, X., Yi, S., Xu, L., Jiang, L., Zhao, C., Dong, X., Zhou, P., Li, S., Wang, S., ... Liu, J. (2014). Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. Oncotarget, 5(14), 5453-5471. https://doi.org/10.18632/oncotarget.2113

Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. / Liu, Ningning; Li, Xiaofen; Huang, Hongbiao; Zhao, Chong; Liao, Siyan; Yang, Changshan; Liu, Shouting; Song, Wenbin; Lu, Xiaoyu; Lan, Xiaoying; Chen, Xin; Yi, Songgang; Xu, Li; Jiang, Lili; Zhao, Canguo; Dong, Xiaoxian; Zhou, Ping; Li, Shujue; Wang, Shunqing; Shi, Xianping; Dou, Ping Q.; Wang, Xuejun; Liu, Jinbao.

In: Oncotarget, Vol. 5, No. 14, 2014, p. 5453-5471.

Research output: Contribution to journal › Article › peer-review

Liu, N, Li, X, Huang, H, Zhao, C, Liao, S, Yang, C, Liu, S, Song, W, Lu, X, Lan, X, Chen, X, Yi, S, Xu, L, Jiang, L, Zhao, C, Dong, X, Zhou, P, Li, S, Wang, S, Shi, X, Dou, PQ, Wang, X & Liu, J 2014, 'Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth', Oncotarget, vol. 5, no. 14, pp. 5453-5471. https://doi.org/10.18632/oncotarget.2113

Liu, Ningning ; Li, Xiaofen ; Huang, Hongbiao ; Zhao, Chong ; Liao, Siyan ; Yang, Changshan ; Liu, Shouting ; Song, Wenbin ; Lu, Xiaoyu ; Lan, Xiaoying ; Chen, Xin ; Yi, Songgang ; Xu, Li ; Jiang, Lili ; Zhao, Canguo ; Dong, Xiaoxian ; Zhou, Ping ; Li, Shujue ; Wang, Shunqing ; Shi, Xianping ; Dou, Ping Q. ; Wang, Xuejun ; Liu, Jinbao. / Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. In: Oncotarget. 2014 ; Vol. 5, No. 14. pp. 5453-5471.

@article{ace1ee968a99441cbe2a730a38fb06e1,

title = "Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth",

abstract = "Proteasomes are attractive emerging targets for anti-cancer therapies. Auranofin (Aur), a gold-containing compound clinically used to treat rheumatic arthritis, was recently approved by US Food and Drug Administration for Phase II clinical trial to treat cancer but its anti-cancer mechanism is poorly understood. Here we report that (i) Aur shows proteasome-inhibitory effect that is comparable to that of bortezomib/Velcade (Vel); (ii) different from bortezomib, Aur inhibits proteasome-associated deubiquitinases (DUBs) UCHL5 and USP14 rather than the 20S proteasome; (iii) inhibition of the proteasome-associated DUBs is required for Aur-induced cytotoxicity; and (iv) Aur selectively inhibits tumor growth in vivo and induces cytotoxicity in cancer cells from acute myeloid leukemia patients. This study provides important novel insight into understanding the proteasome-inhibiting property of metal-containing compounds. Although several DUB inhibitors were reported, this study uncovers the first drug already used in clinic that can inhibit proteasome-associated DUBs with promising anti-tumor effects.",

keywords = "Auranofin, Cancer, Deubiquitinase, Proteasome",

author = "Ningning Liu and Xiaofen Li and Hongbiao Huang and Chong Zhao and Siyan Liao and Changshan Yang and Shouting Liu and Wenbin Song and Xiaoyu Lu and Xiaoying Lan and Xin Chen and Songgang Yi and Li Xu and Lili Jiang and Canguo Zhao and Xiaoxian Dong and Ping Zhou and Shujue Li and Shunqing Wang and Xianping Shi and Dou, {Ping Q.} and Xuejun Wang and Jinbao Liu",

year = "2014",

doi = "10.18632/oncotarget.2113",

language = "English (US)",

volume = "5",

pages = "5453--5471",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals",

number = "14",

}

TY - JOUR

T1 - Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth

AU - Liu, Ningning

AU - Li, Xiaofen

AU - Huang, Hongbiao

AU - Zhao, Chong

AU - Liao, Siyan

AU - Yang, Changshan

AU - Liu, Shouting

AU - Song, Wenbin

AU - Lu, Xiaoyu

AU - Lan, Xiaoying

AU - Chen, Xin

AU - Yi, Songgang

AU - Xu, Li

AU - Jiang, Lili

AU - Zhao, Canguo

AU - Dong, Xiaoxian

AU - Zhou, Ping

AU - Li, Shujue

AU - Wang, Shunqing

AU - Shi, Xianping

AU - Dou, Ping Q.

AU - Wang, Xuejun

AU - Liu, Jinbao

PY - 2014

Y1 - 2014

N2 - Proteasomes are attractive emerging targets for anti-cancer therapies. Auranofin (Aur), a gold-containing compound clinically used to treat rheumatic arthritis, was recently approved by US Food and Drug Administration for Phase II clinical trial to treat cancer but its anti-cancer mechanism is poorly understood. Here we report that (i) Aur shows proteasome-inhibitory effect that is comparable to that of bortezomib/Velcade (Vel); (ii) different from bortezomib, Aur inhibits proteasome-associated deubiquitinases (DUBs) UCHL5 and USP14 rather than the 20S proteasome; (iii) inhibition of the proteasome-associated DUBs is required for Aur-induced cytotoxicity; and (iv) Aur selectively inhibits tumor growth in vivo and induces cytotoxicity in cancer cells from acute myeloid leukemia patients. This study provides important novel insight into understanding the proteasome-inhibiting property of metal-containing compounds. Although several DUB inhibitors were reported, this study uncovers the first drug already used in clinic that can inhibit proteasome-associated DUBs with promising anti-tumor effects.

AB - Proteasomes are attractive emerging targets for anti-cancer therapies. Auranofin (Aur), a gold-containing compound clinically used to treat rheumatic arthritis, was recently approved by US Food and Drug Administration for Phase II clinical trial to treat cancer but its anti-cancer mechanism is poorly understood. Here we report that (i) Aur shows proteasome-inhibitory effect that is comparable to that of bortezomib/Velcade (Vel); (ii) different from bortezomib, Aur inhibits proteasome-associated deubiquitinases (DUBs) UCHL5 and USP14 rather than the 20S proteasome; (iii) inhibition of the proteasome-associated DUBs is required for Aur-induced cytotoxicity; and (iv) Aur selectively inhibits tumor growth in vivo and induces cytotoxicity in cancer cells from acute myeloid leukemia patients. This study provides important novel insight into understanding the proteasome-inhibiting property of metal-containing compounds. Although several DUB inhibitors were reported, this study uncovers the first drug already used in clinic that can inhibit proteasome-associated DUBs with promising anti-tumor effects.

KW - Auranofin

KW - Cancer

KW - Deubiquitinase

KW - Proteasome

UR - http://www.scopus.com/inward/record.url?scp=84906249813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906249813&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.2113

DO - 10.18632/oncotarget.2113

M3 - Article

C2 - 24977961

AN - SCOPUS:84906249813

VL - 5

SP - 5453

EP - 5471

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 14

ER -

Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this